0.49 (-%)
As of Oct 31, 2024
Source:
We are a dermatology company focused on identifying, developing and commercializing investigational and generic topical drug products for the treatment of skin diseases. In addition to Twyneo, which has been approved by the FDA, our current product candidate pipeline consists of clinical stage and early-stage investigational product candidates, some of which leverage our development platform, and several generic product candidates across multiple indications.
Country | Israel |
Headquarters | ness ziona |
Phone Number | 97289313433 |
Industry | manufacturing |
CEO | Alon Seri-Levy |
Website | sol-gel.com. |